Literature DB >> 10995046

Determinants of bone density in healthy older men with low testosterone levels.

A M Kenny1, K M Prestwood, K M Marcello, L G Raisz.   

Abstract

BACKGROUND: Osteoporosis is a significant problem in older men, 30% of all hip fractures occur in men and the mortality rate following hip fracture exceeds that of women. Testosterone is thought to be important in the development of peak bone mass hut its role in age-related bone loss is not established. The purpose of this study was to define the predictors of bone mass ill healthy older men with low testosterone levels but without symptomatic osteoporosis.
METHODS: Eighty-three community-dwelling white men, aged more than 65 years old, selected for low bioavailable testosterone levels (< or = 4.44 nmol/l) participated in a cross-sectional study located at a university general clinical research center. Sex hormone concentrations and markers of bone turnover were assayed in serum and urine. Risk factors for osteoporosis and physical activity were ascertained by physical examination and questionnaire, including the Physical Activity Scale in the Elderly (PASE) questionnaire. Bone mineral densities of the femoral neck (FN BMD), spine, and whole body were measured by dual x-ray absorptiometry. Lower extremity muscle strength (1 repetition maximum) was measured using a leg press machine.
RESULTS: Mean bone mineral density values were 0.93 +/- 0.14 g/cm2 for femoral neck, 1.31 +/- 0.23 g/cm2 for spine, and 1.22 +/- 0.12 g/cm2 for whole body. Thirty-one of the 82 subjects (37%) had t scores < -1 and 12 of 82 subjects (15%) had t scores < -2.5 at the femoral neck. Multiple linear regression analysis demonstrated that bioavailable testosterone, body mass index (BMI), and PASE scores were positively correlated with, and significant predictors of, femoral neck BMD, accounting for 34.4% of the variance in FN BMD (F = 10.10, p = .001). Examining each variable independently, bioavailable testosterone accounted for 20.7%, physical activity score for 9.0%, and BMI for 6.5% of FN BMD. Using analysis of variance, mean values for FN BMD were significantly different between men grouped by tertile of bioavailable testosterone (F = 6.192, p = .003). FN BMD mean values were 0.86 +/- 0.14 g/cm2 for the lowest tertile, 0.94 +/- 0.16 for the middle tertile, and 0.99 +/- 0.14 for the highest tertile. Markers of bone turnover were inversely correlated, and strength directly correlated with BMD, but did not contribute to the multiple regression model.
CONCLUSIONS: Fifty-two percent of older men with low bioavailable testosterone levels had BMD levels below the young adult normal range and are likely at an increased risk of fracture. Bioavailable testosterone, BMI, and physical activity scores were significant determinants of FN BMD in these men. These variables are potentially modifiable and, therefore, amenable to intervention. Hence, our results suggest the need for testosterone replacement and physical activity intervention trials in men at risk for osteoporotic fractures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995046     DOI: 10.1093/gerona/55.9.m492

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  20 in total

1.  Alendronate for osteoporosis in men with androgen-repleted hypogonadism.

Authors:  Ilan Shimon; Varda Eshed; Ram Doolman; Ben-Ami Sela; Avraham Karasik; Iris Vered
Journal:  Osteoporos Int       Date:  2005-03-15       Impact factor: 4.507

2.  Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.

Authors:  L T Nguyen; U D T Nguyen; T D T Nguyen; L T Ho-Pham; T V Nguyen
Journal:  Osteoporos Int       Date:  2018-09-08       Impact factor: 4.507

3.  Positive associations of bone mineral density with body mass index, physical activity, and blood triglyceride level in men over 70 years old: a TCVGHAGE study.

Authors:  Yih-Jing Tang; Wayne Huey-Herng Sheu; Pi-Haw Liu; Wen-Jane Lee; Ying-Tsung Chen
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

Review 4.  Androgens and bone.

Authors:  Bart L Clarke; Sundeep Khosla
Journal:  Steroids       Date:  2008-10-17       Impact factor: 2.668

5.  Muscle-Bone Interactions Across age in Men.

Authors:  Ian J Palmer; Eric D Runnels; Michael G Bemben; Debra A Bemben
Journal:  J Sports Sci Med       Date:  2006-03-01       Impact factor: 2.988

Review 6.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

7.  Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men.

Authors:  Channing J Paller; Meredith S Shiels; Sabine Rohrmann; Shehzad Basaria; Nader Rifai; William Nelson; Elizabeth A Platz; Adrian Dobs
Journal:  Clin Endocrinol (Oxf)       Date:  2008-05-14       Impact factor: 3.478

8.  Relative contributions of multiple determinants to bone mineral density in men.

Authors:  G R Chiu; A B Araujo; T G Travison; S A Hall; J B McKinlay
Journal:  Osteoporos Int       Date:  2009-03-25       Impact factor: 4.507

Review 9.  The osteoporotic male: overlooked and undermanaged?

Authors:  Bruno Madeo; Lucia Zirilli; Giovanni Caffagni; Chiara Diazzi; Alessia Sanguanini; Elisa Pignatti; Cesare Carani; Vincenzo Rochira
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.